Department of Respiratory and Critical Care Medicine, Xi'an Jiaotong University Second Affiliated Hospital, Xi'an, China.
Department of Respiratory and Critical Care Medicine, Yulin No.2 Hospital, Yulin, China.
Front Immunol. 2024 Nov 1;15:1439830. doi: 10.3389/fimmu.2024.1439830. eCollection 2024.
Numerous studies have established that probiotics or prebiotics can relieve the symptoms of allergic rhinitis (AR), but their mechanism of action remain underexplored. This study aimed to observe the clinical efficacy of probiotics combined with prebiotics in seasonal AR patients and explore their underlying mechanisms.
We conducted a prospective, randomized, double-blind, placebo-controlled clinical trial. The test group was given probiotics combined with prebiotics, whereas the placebo group was administered simulated preparation for 90 days. Outcome measures included total nasal symptom score (TNSS), visual analog scale, rhinitis quality of life questionnaire, fractional exhaled nitric oxide, and the rate and intensity of Loratadine use. Serum TNF-α, INF-γ, IL-4, IL-17, and IgE levels were measured by enzyme-linked immunosorbent assay. Intestinal microbiota was detected by 16S rRNA gene sequencing and quantitative PCR. Short-chain fatty acids were analyzed by gas chromatography-mass spectrometry.
106 participants (N = 53 for both test group and placebo group) completed the study. From baseline to day 91, mean difference between groups (MDBG) in the reduction of TNSS was -1.1 (-2.2, -0.1) (P = 0.04); MDBG in the increment of TNF-α was 7.1 pg/ml (95% CI: 0.8, 13.4, P = 0.03); the INF-γ level was significantly increased (P = 0.01), whereas that of IL-17 (P = 0.005) was significantly decreased in the test group, whilst mean difference within groups was not statistically significant in the placebo group; MDBG in the increment of acetate was 12.4% (95% CI: 7.1%, 17.6%, P <0.001). After the administration of probiotics and prebiotics, the composition and metabolic function of the intestinal microbiota were significantly altered and positively related to the beneficial effect on seasonal AR patients.
Probiotics combined with prebiotics administered for 90 days significantly attenuated the symptoms of seasonal AR patients, which may related to fluctuations in the composition and metabolic function of the intestinal microbiota and further ameliorating host immunity.
许多研究已经证实益生菌或益生元可以缓解过敏性鼻炎(AR)的症状,但它们的作用机制仍未得到充分探索。本研究旨在观察益生菌联合益生元治疗季节性 AR 患者的临床疗效,并探讨其潜在机制。
我们进行了一项前瞻性、随机、双盲、安慰剂对照的临床试验。实验组给予益生菌联合益生元治疗,而安慰剂组给予模拟制剂治疗 90 天。观察指标包括总鼻症状评分(TNSS)、视觉模拟评分、鼻炎生活质量问卷、呼出气一氧化氮分数(FeNO)以及氯雷他定的使用频率和强度。采用酶联免疫吸附试验检测血清 TNF-α、IFN-γ、IL-4、IL-17 和 IgE 水平。采用 16S rRNA 基因测序和实时定量 PCR 检测肠道菌群。采用气相色谱-质谱联用技术分析短链脂肪酸。
106 名参与者(实验组和安慰剂组各 53 名)完成了研究。从基线到第 91 天,TNSS 降低的组间平均差异(MDBG)为-1.1(-2.2,-0.1)(P = 0.04);TNF-α 增加的 MDBG 为 7.1pg/ml(95%CI:0.8,13.4,P = 0.03);IFN-γ 水平显著升高(P = 0.01),而实验组的 IL-17 水平显著降低(P = 0.005),而安慰剂组的组内差异无统计学意义;乙酸增加的 MDBG 为 12.4%(95%CI:7.1%,17.6%,P <0.001)。益生菌和益生元治疗后,肠道微生物群的组成和代谢功能发生显著改变,并与对季节性 AR 患者的有益作用呈正相关。
益生菌联合益生元治疗 90 天可显著减轻季节性 AR 患者的症状,这可能与肠道微生物群的组成和代谢功能的波动有关,并进一步改善宿主免疫。